Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells

Clinica Chimica Acta

Volumn 377, Issue 1-2, 2007, Pages 144-149

  Kanno, Syu ichi ^a   Hiura, Takako ^a   Ohtake, Takaharu ^a   Koiwai, Kimiko ^a   Suzuki, Hiroyoshi ^b   Ujibe, Mayuko ^a   Ishikawa, Masaaki ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Ara C; Cytidine deaminase; Deoxycytidine kinase; Human equilibrative nucleoside transporter 1; NALM 6 cells; Resistant

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; MESSENGER RNA; NUCLEOSIDE DERIVATIVE; RADIOISOTOPE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; CELL SURVIVAL; CYTARABINE; CYTIDINE DEAMINASE; CYTOPROTECTION; DEOXYCYTIDINE KINASE; DIPYRIDAMOLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; LEUKEMIA; RNA, MESSENGER; THIOINOSINE;

ARA;

EID: 33845418417     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.09.014     Document Type: Article

References (34)

1. Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res 72 (1998) 197-233
2. Cass C.E., Young J.D., and Baldwin S.A. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem Cell Biol 76 (1998) 761-770
3. Wiley J.S., Jones S.P., Sawyer W.H., and Paterson A.R. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 69 (1982) 479-489
4. White J.C., Rathmell J.P., and Capizzi R.L. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Clin Invest 79 (1987) 380-387
5. Gati W.P., Paterson A.R., Larratt L.M., Turner A.R., and Belch A.R. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 90 (1997) 346-353
6. Harris A.L., and Grahame-Smith D.G. The relationship of Ara-C metabolism in vitro to therapeutic response in acute myeloid leukaemia. Cancer Chemother Pharmacol 9 (1982) 30-35
7. Rustum Y.M., and Raymakers R.A. 1-Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol Ther 56 (1992) 307-321
8. Kanno S., Higurashi A., Watanabe Y., Shouji A., Asou K., and Ishikawa M. Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell lines. Toxicol Lett 152 (2004) 149-158
9. Schiffer C.A. Treatment of high-grade lymphoid malignancies in adults. Semin Hematol 38 (2001) 22-26
10. Ponte P., Ng S.Y., Engel J., Gunning P., and Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 12 (1984) 1687-1696
11. Huang M., Wang Y., Collins M., Gu J.J., Mitchell B.S., and Graves L.M. Inhibition of nucleoside transport by p38 MAPK inhibitors. J Biol Chem 277 (2002) 28364-28367
12. Cheng Y.C., and Lee L.S. Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients. Biochim Biophys Acta 481 (1977) 481-492
13. Perignon J.L., Chaleon J., Leverger G., Houllier A.M., Thuillier L., and Cartier P.H. Cytidine deaminase activity of human normal and malignant lymphoid cells. Clin Chim Acta 147 (1985) 67-74
14. Kanno S., Ishikawsa M., Takayanagi M., Takayanagi Y., and Sasaki K. Potentiation of acetaminophen hepatotoxicity by doxapram in mouse primary cultured hepatocytes. Biol Pharm Bull 23 (2000) 446-450
15. Paterson A.R.P., Lau E.Y., Dahlig E., and Cass C.E.A. A common basis for inhibition of nucleoside transport by dipyridamole and nitrobenzylthioinosine?. Mol Pharmacol 18 (1980) 40-44
16. King M.E., Naporn A., Young B., and Howell S.B. Modulation of cytarabine uptake and toxicity by dipyridamole. Cancer Treat Rep 68 (1984) 361-366
17. Kubota M., Takimoto T., Kitoh T., et al. Prevention of 1-beta-D arabinofuranosylcytosine toxicity by 4-nitrobenzyl-6-thioinosine or dipyridamole in human leukemia cell lines. Anticancer Res 8 (1988) 339-342
18. Capizzi R.L., Yang J.L., Cheng E., et al. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1 (1983) 763-771
19. Podgorska M., Kocbuch K., and Pawelczyk T. Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol 52 4 (2005) 749-758
20. Coleman C.N., Stoller R.G., Drake J.C., and Chabner B.A. Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood 46 (1975) 791-803
21. Kakihara T., Fukuda T., Tanaka A., et al. Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. Leuk Lymphoma 31 (1998) 405-409
22. Owens J.K., Shewach D.S., Ullman B., and Mitchell B.S. Resistance to 1-beta-d-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 52 (1992) 2389-2393
23. Stegmann A.P., Honders M.W., Kester M.G., Landegent J.E., and Willemze R. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-d-arabinofuranosylcytosine and 5-aza-2′-deoxycytidine. Leukemia 7 (1993) 1005-1011
24. Kawasaki H., Shindou K., Higashigawa M., et al. Deoxycytidine kinase mRNA levels in leukemia cells with competitive polymerase chain reaction assay. Leuk Res 20 (1996) 677-682
25. Neff T., and Blau C.A. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 24 (1996) 1340-1646
26. Schroder J.K., Kirch C., Flasshove M., et al. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia 10 (1996) 1919-1924
27. Momparler R.L., Laliberte J., Eliopoulos N., Beausejour C., and Cournoyer D. Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside. Anticancer Drugs 7 (1996) 266-274
28. Galmarini C.M., Mackey J.R., and Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15 (2001) 875-890
29. Lotfi K., Mansson E., Peterson C., Eriksson S., and Albertioni F. Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-d-arabinofuranosylguanine cytotoxicity. Biochem Biophys Res Commun 293 (2002) 1489-1496
30. Hu X.F., Slater A., Kantharidis P., et al. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 93 (1999) 4086-4095
31. Hait W.N., Choundhury S., Srimatkandada S., and Murren J.R. Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents. J Clin Invest 91 (1993) 2207-2215
32. Baldwin S.A., Mackey J.R., Cass C.E., and Young J.D. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 5 (1999) 216-224
33. Mackey J.R., Jennings L.L., Clarke M.L., et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res 8 1 (2002) 110-116
34. Agarwal R.P., Han T., and Fernandez M. Reduced cellular transport and activation of fluoropyrimidine nucleoside and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol 61 (2001) 39-47